[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Tasmania\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100641535","perceive-outreach-a-scalable-risk-based-model-for-managing-persistent-cardiovascular-impact-in-long-covid-100641535",false,"NCT07661862","PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID","Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID","Inclusion Criteria:\n\n* Aged forty years or older\n* Impaired estimated functional capacity using DASI as proxy (defined by age-normative metabolic equivalent of tasks \\[METs\\])\n* History of COVID-19 (stratified by hospital admission)\n* Currently symptomatic with fatigue, dyspnoea or chest pain symptoms\n* Medicare eligibility\n* Ability and willingness to provide written informed consent to participate in the study. The patient will need to be able to communicate fluently with the investigator. The investigator will need to be satisfied that the patient understands the study by having them explain the study plan back to the investigator.\n\nExclusion Criteria:\n\n* Unable to provide written informed consent to participate in this study\n* Participating in another research trial where randomized treatment would be unacceptable\n* Mobility impairment that would impact participants' ability to perform exercise\n* History of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS)\n* Known valvular stenosis or regurgitation of \\>moderate severity, history of previous heart failure (baseline New York Heart Association \\[NYHA\\] \\>2)\n* Oncologic (or other) life expectancy \\\u003C12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial","ALL","40 Years",{"count":19,"type":20},577,"ESTIMATED","INTERVENTIONAL",[23],"NA","Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called \"Long COVID\" or Post-Acute Sequelae of SARS-CoV-2 (PASC). For some people, Long COVID can affect the heart and lungs, making it harder to exercise or carry out daily activities. It can also affect mental health and quality of life.\n\nThis study is testing a new care model called PERCEIVE-Outreach, designed to help people living with Long COVID who may have ongoing heart or lung problems. The model involves three parts:\n\n1. Screening: A simple assessment to identify people most likely to benefit from further care, based on symptoms and activity levels.\n2. Clinical review: A thorough check of heart and lung health conducted remotely via telehealth.\n3. Personalised exercise program: A tailored program to help improve fitness and reduce time spent sitting, delivered entirely via telehealth.\n\nThe main thing this study is measuring is whether participants can walk further after 6 months compared to when they started (measured using a 6-minute walk test), which correlates well with an individuals ability to complete normal daily functions. The study will also look at quality of life, mental health, physical activity, heart function, and hospital visits over 2 years.\n\nThe study is designed with input from patients and healthcare providers to ensure it meets real-world needs. All care is delivered remotely, meaning participants can take part from home anywhere in Australia.",[26],"Long COVID",[26,28,29,30,31,32,33],"Exercise","PERCEIVE-Outreach","PERCEIVE","Australia","Rural Health","Cardiovascular","RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2026-04-01",{"date":42,"type":20},"2029-04-01",{"name":44,"class":45},"University of Tasmania","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100454226","tas-test-online-motor-cognitive-tests-for-early-detection-of-alzheimers-disease-100454226","NCT05194787","TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease","TAS Test: Determining the Feasibility and Validity of Online Motor-cognitive Testing for Early Detection of Alzheimer's Disease","TASTest","Inclusion Criteria: \\> 50years old\n\nExclusion Criteria: established diagnosis of dementia",true,"50 Years",{"count":57,"type":20},3000,"OBSERVATIONAL","Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life. AD has a preclinical (pre-AD) period of 10-20 years when brain pathology silently progresses before any cognitive symptoms appear. Current tests for pre-AD are invasive, costly and unsuitable for screening at population level. Similar to screening for pre-diabetes and carcinoma in situ, it is important to detect AD at the preclinical stage in order to offer early interventions before the pathology progresses to the irrerversible degenerative stage. In the study, research will develop a new scalable test (TAS Test) by combining two innovative ideas: hand-movement tests to detect pre-AD \\>10 years before cognitive symptoms begin; and computer vision so people can \"self-test\" online using home computers. This unique approach builds on recent discoveries that hand-movement patterns change in pre-AD. The research team will use exquisitely precise computer vision methods to automatically analyse movement data from thousands of participants, and combine this with machine learning of overall motor-cognitive performance. The project team has access to 3 well-phenotyped cohorts, \\>10,000 existing participants and a cutting-edge assay for a blood AD biomarker, ptau181. The research team will develop a TAS Test algorithm to classify hand-movement and cognitive test data for pre-AD risk (p-taua181 levels) and determine TAS Test's precision to prospectively predict 5-year risks of cognitive decline and AD.",[61,62,63],"Alzheimer Disease","Dementia","Age-related Cognitive Decline",[65,66,67,68],"pre-clinical","early detection","online tests","Artificial intelligence","2023-10-27",{"date":71,"type":38},"2023-10-30",{"date":73,"type":38},"2021-03-05",{"date":75,"type":20},"2030-12",{"name":44,"class":45},1,""]